[{"address1": "One Corporate Drive", "address2": "2nd Floor", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "800 466 6059", "website": "https://www.aligos.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-\u00df agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. It also has a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 68, "companyOfficers": [{"maxAge": 1, "name": "Dr. Lawrence M. Blatt MBA, Ph.D.", "age": 62, "title": "CEO, President & Chairman of the Board", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 1032768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Julian A. Symons DPHIL", "age": 63, "title": "Executive VP & Chief Scientific Officer", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 735515, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristina  Engeseth M.B.A.", "title": "VP and Head of People & Culture", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushmita M. Chanda DABT, Ph.D.", "age": 57, "title": "Executive Vice President & Chief Development Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David B. Smith Ph.D.", "title": "Executive VP & Head of Chemical Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Tse-I  Lin Ph.D.", "title": "VP of Early Compound Development & Belgian Site Head", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hardean E. Achneck M.D.", "title": "Chief Medical Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1738368000, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 20.85, "open": 21.47, "dayLow": 18.13, "dayHigh": 21.88, "regularMarketPreviousClose": 20.85, "regularMarketOpen": 21.47, "regularMarketDayLow": 18.13, "regularMarketDayHigh": 21.88, "payoutRatio": 0.0, "beta": 2.457, "forwardPE": -1.5595638, "volume": 312694, "regularMarketVolume": 312639, "averageVolume": 361313, "averageVolume10days": 252870, "averageDailyVolume10Day": 252870, "bid": 18.35, "ask": 18.86, "bidSize": 1, "askSize": 1, "marketCap": 66698876, "fiftyTwoWeekLow": 6.76, "fiftyTwoWeekHigh": 46.8, "priceToSalesTrailing12Months": 11.122041, "fiftyDayAverage": 31.6445, "twoHundredDayAverage": 17.881025, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 9018548, "profitMargins": 0.0, "floatShares": 1892936, "sharesOutstanding": 3464200, "sharesShort": 576358, "sharesShortPriorMonth": 597297, "sharesShortPreviousMonthDate": 1735603200, "dateShortInterest": 1738281600, "sharesPercentSharesOut": 0.16059999, "heldPercentInsiders": 0.17799, "heldPercentInstitutions": 0.46767, "shortRatio": 1.66, "shortPercentOfFloat": 0.2565, "impliedSharesOutstanding": 3587890, "bookValue": 15.067, "priceToBook": 1.2338222, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -76953000, "trailingEps": -7.25, "forwardEps": -11.92, "lastSplitFactor": "1:25", "lastSplitDate": 1724025600, "enterpriseToRevenue": 1.504, "enterpriseToEbitda": -0.097, "52WeekChange": 0.11199999, "SandP52WeekChange": 0.2021538, "quoteType": "EQUITY", "currentPrice": 18.59, "targetHighPrice": 175.0, "targetLowPrice": 60.0, "targetMeanPrice": 103.33333, "targetMedianPrice": 75.0, "recommendationKey": "none", "numberOfAnalystOpinions": 3, "totalCash": 74922000, "totalCashPerShare": 20.882, "ebitda": -92684000, "totalDebt": 9133000, "quickRatio": 3.575, "currentRatio": 3.809, "totalRevenue": 5997000, "debtToEquity": 18.231, "revenuePerShare": 1.005, "returnOnAssets": -0.67323, "returnOnEquity": -1.4669299, "grossProfits": -70498000, "freeCashflow": -49061000, "operatingCashflow": -84998000, "revenueGrowth": -0.608, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -15.863669, "financialCurrency": "USD", "symbol": "ALGS", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Aligos Therapeutics, Inc.", "longName": "Aligos Therapeutics, Inc.", "regularMarketChangePercent": -10.83933, "regularMarketPrice": 18.59, "regularMarketTime": 1740170708, "exchange": "NCM", "messageBoardId": "finmb_581475891", "corporateActions": [], "marketState": "REGULAR", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1602855000000, "regularMarketChange": -2.2600002, "fiftyDayAverageChange": -13.054501, "fiftyDayAverageChangePercent": -0.41253614, "twoHundredDayAverageChange": 0.70897484, "twoHundredDayAverageChangePercent": 0.039649565, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "ipoExpectedDate": "2020-10-16", "cryptoTradeable": false, "regularMarketDayRange": "18.13 - 21.88", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 361313, "fiftyTwoWeekLowChange": 11.83, "fiftyTwoWeekLowChangePercent": 1.7499999, "fiftyTwoWeekRange": "6.76 - 46.8", "fiftyTwoWeekHighChange": -28.21, "fiftyTwoWeekHighChangePercent": -0.6027778, "fiftyTwoWeekChangePercent": 11.199999, "earningsTimestampStart": 1741604340, "earningsTimestampEnd": 1741953600, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -7.25, "epsForward": -11.92, "epsCurrentYear": -10.36, "priceEpsCurrentYear": -1.7944016, "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Aligos Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-02-21"}]